Breaking the Fog, Building Bridges: Commercial Navigation for China's Global Biotech
With over 45 years of close collaboration with Multinational Pharmaceutical Companies (MNCs), Michael Allen Company (MAC) possesses deep insight into the underlying logic and decision-making processes pharma giants use to value new products.
China’s innovative biotech companies have world-class R&D capabilities, yet often lack a transparent understanding of the status quo when facing unfamiliar Western markets. At MAC, we are not just your guide, but your strategic gatekeeper, helping you scrutinize your assets through the eyes of MNCs and payers, connecting you with global resources to maximize the realization of your innovation’s value.
Step 1: Clearing the Fog — Reshaping Value Assessment with the "Grader's" Standards
The primary challenge of going global is often ‘cognitive bias.’ Is what looks like a highlight to a Chinese biotech actually a value point for a US Pharma or Payer? We don’t just have data; we hold the “grading standards + scoring rubric” used in US market decision-making.
WayFinder℠: Precision Navigation for Transaction and Partnership Decisions
Core Question: If we ran our data through a Pfizer or Merck-level due diligence model, would it hold up?
WayFinder℠ is your “value compass” and your “mock exam.” We apply the exact modeling frameworks we use when conducting due diligence for top-tier MNCs, combined with real-world claims data, to validate and pressure-test every key assumption in your Business Plan (BP):
- TAM & Market Share: Is the target patient pool accurate? Do share projections align with historical competitor trends?
- Line of Therapy (LOT): In the real-world treatment pathway, will physicians actually switch to your therapy at this line?
- IRA Impact: What is the substantial impact of the Inflation Reduction Act on your pricing ceiling?
This ‘MNC-level rehearsal’ ensures that when you step onto the negotiation table, you hold ‘ironclad evidence’ capable of withstanding any challenge.
ViewFinder™ Opportunity & Patient Journey Analytics
Core Question: What are the real unmet needs in the overseas market? Where should we focus our efforts?
We go beyond market sizing to map the ‘full picture’ of the market. By analyzing the complete patient journey, we quantify opportunities and barriers at every step, identifying the most valuable intervention points. This ensures your clinical development and market strategy target the highest-value opportunities from day one, avoiding wasted resources.
Step 2: Leveraging Strengths — Transforming Clinical Advantages into Commercial Wins
Superior clinical data is the foundation, but not the whole story. You need a “value story” that is understood and recognized by overseas physicians and patients as well as Payers. We help you leverage your strengths and precisely convey your pipeline’s advantages to every decision-maker in the target market.
ViewFinder™ Decision Driver & Segmentation Analysis
Core Question: What matters most to overseas physicians and payers? How do we make our value story hit the mark?
At MAC, we dig deep into the core drivers of prescribing decisions to help you understand the mindset of your target audience. Through precise market segmentation, we help you craft the most persuasive messaging for different types of physicians and patients, allowing them to clearly see the unique value of your product. We can even link segmentation results to CRM systems to pave the way for future commercial promotion.
Step 3: Facing the 'Gatekeepers' — Planning Access & Pricing with Real Data
In overseas markets, especially the US, payers are the ‘gatekeepers’, essentially determining the success or failure of your product in market. We understand what they care about and utilize real-world claims & payer policy data to reconstruct a clear landscape for you.
Precise Pricing Strategy & Budget Planning
Core Question: What is the current coverage status among major Payers? How much Rebate budget do we need to unlock the market?
We don’t deal in abstract theories. We use data to map the current coverage landscape (including tier status, prior authorization, and step edits) of major payers and Pharmacy Benefit Managers (PBMs) in your therapeutic area. Based on this, we assist you in precise decision planning, including:
- Defining a reasonable pricing range aligned with market realities;
- Calculating the rebate budget required to achieve ideal coverage;
- Anticipating potential access barriers and formulating corresponding negotiation chips.
Direct Access to Payer Decision-Makers
Core Question: How can we hear the real voice of key decision-makers before launch to avoid risks?
We have access to an exclusive network of over 2,200 US managed care decision-makers, covering commercial plans, PBMs, and government payers (Medicare/Medicaid). Through us, you can speak directly with these key figures before launch to test value propositions or even conduct mock Pharmacy & Therapeutics (P&T) reviews. This “pre-launch drill” allows you to spot strategic blind spots early and avoid expensive detours after launch.
Step 4: Building Bridges — Connecting with Global Best-in-Class Resources
Our unique position lies in serving two types of clients simultaneously: Chinese innovative biotechs that are seeking to go global, and international pharma giants actively scouting for quality assets. We are not just matchmakers; we are strategic designers.
Empowering Collaboration: Building a "1+1>2" Strategic Combination
Core Question: How do we make MNCs instantly see the strategic accretion our product adds to their existing pipeline?
We know that when global pharma giants evaluate potential partnership projects, they often look beyond individual product merit to portfolio synergy. Based on a deep understanding of global pharma strategic layouts, we help you to draw a clear strategic puzzle for you:
“ Your Asset + MNC Existing Pipeline = Stronger Franchise ”
Through the rigorous data validation and access strategy planning outlined above, we help you to prepare an impeccable and accessible ‘business case’ for you — using language MNCs understand, to prove how this combination will consolidate their market leadership. This not only significantly enhances your asset’s appeal but serves as a key lever to secure the most favorable terms in partnership negotiations.